Monitor enrollment and interim data from the global UPSTREAM MG Phase 3 trial, which is the key catalyst for potential US/EU/Japan regulatory filings. No financial guidance or deal value disclosed.
Price Chart
Executive Summary
Vor Bio announced positive post hoc Phase 3 data for telitacicept in generalized myasthenia gravis, showing >94% of participants achieved ≥5-point MG-ADL improvement at Week 48 and 42% achieved minimal symptom expression (MSE) with high durability. The data strengthens the case for the global Phase 3 UPSTREAM MG trial, but the filing is a press release with no new regulatory milestone or financial data.
Key Facts
- >94% of participants achieved ≥5-point MG-ADL improvement at Week 48
- 42% of telitacicept-treated participants achieved MSE at any time over 48 weeks
- 86.7% of MSE events sustained at next monthly assessment; participants spent 83-85% of remaining follow-up in MSE
- 51% of participants with baseline MG-ADL 6-10 and 21% with ≥11 achieved MSE
- Telitacicept is approved in China for SLE, RA, gMG, IgAN, and SjD; Vor Bio is advancing global Phase 3 trials in gMG and SjD
Financial Impact
No financial data provided; clinical-stage company with no revenue from telitacicept in US/EU/Japan
Risk Factors
- Phase 3 global trial may fail to replicate Chinese Phase 3 results
- Regulatory approval in US/EU/Japan is uncertain and years away
- Competition from approved gMG therapies (e.g., efgartigimod, ravulizumab) may limit commercial potential
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3370807 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $18.26 $18.33 | ▲ +0.38% | ▼ −0.33% | $18.33 (+0.38%) |
Oct 5, 2026 21d ago | Press Release | $18.31 $18.78 | ▲ +2.57% | ▲ +2.81% | $18.33 (+0.11%) |
Sep 29, 2026 27d ago | Press Release | $18.33 $19.08 | ▲ +4.09% | ▲ +4.30% | $18.33 (−0.00%) |
Aug 11, 2026 10w ago | Press Release | $23.37 $22.34 | ▼ −4.41% | ▼ −4.66% | $18.33 (−21.57%) |
Jul 9, 2026 15w ago | 3 | $19.14 $18.03 | ▼ −5.80% | ▼ −5.03% | $18.33 (−4.23%) |
Jun 11, 2026 19w ago | Institutional Cluster | $14.09 $14.36 | ▲ +1.92% | ▲ +1.38% | $18.33 (+30.09%) |
Jun 8, 2026 20w ago | Press Release | $13.29 $13.28 | ▼ −0.08% | ▲ +0.22% | $18.33 (+37.92%) |
May 7, 2026 24w ago | EFFECT | $16.08 $16.94 | ▲ +5.35% | ▲ +4.52% | $18.33 (+13.99%) |
Apr 27, 2026 26w ago | S-3 | $14.38 $14.11 | ▼ −1.88% | ▼ −1.87% | $18.33 (+27.47%) |
Apr 27, 2026 26w ago | DEFA14A | $14.38 $14.11 | ▼ −1.88% | ▼ −1.87% | $18.33 (+27.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers